Targeting XRCC1 Deficiency in Breast Cancer for Personalized TherapyRebeka Sultana, Srinivasan Madhusudan, Tarek M.A. Abdel-Fatah et al.|Cancer Research|2012Cited by 101
Synthetic lethal targeting of DNA double‐strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitorsRebeka Sultana, Srinivasan Madhusudan, Daniel R. McNeill et al.|International Journal of Cancer|2012Cited by 94
Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer CellsRebeka Sultana, Srinivasan Madhusudan, Tarek M.A. Abdel-Fatah et al.|PLoS ONE|2013Cited by 85
Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapyNada Albarakati, Srinivasan Madhusudan, Tarek M.A. Abdel-Fatah et al.|Molecular Oncology|2014Cited by 80
Clinicopathological and functional significance of XRCC1 expression in ovarian cancerTarek M.A. Abdel-Fatah, Srinivasan Madhusudan, Rebeka Sultana et al.|International Journal of Cancer|2012Cited by 64